Last updated: October 25, 2023
Sponsor: Fudan University
Overall Status: Active - Not Recruiting
Phase
3
Condition
Lung Disease
Cancer
Lung Cancer
Treatment
Wedge resection
Clinical Study ID
NCT06102161
WGGO
Ages 18-80 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who sign the informed consent form and are willing to complete the studyaccording to the plan;
- Aged from 18 to 80 years old;
- ECOG equals 0 or 1;
- Not receiving lung cancer surgery before;
- Intraoperative or postoperative pathologic diagnosis of lung adenocarcinoma;
- Single lung nodules with ground-glass dominant or pure ground-glass on CT, or multiplelung nodules with the major lesion being the aforementioned nodules;
- The nodule has a consolidation-to-tumor ratio (CTR) between 0.25 and 0.5 (including 0.25 and 0.5), and the nodule size is less than or equal to 2 cm;
- peripheral type of nodes, namely, nodes in the outer 1/3 of the lung field.
- cT1N0M0 tumors;
- Complete tumor resection by wedge resection as assessed by the surgeon;
- Not receiving chemotherapy or radiotherapy before.
Exclusion
Exclusion Criteria:
- Postoperative pathologic diagnosis of adenocarcinoma in situ or minimally invasiveadenocarcinoma.
- CTR is not between 0.25-0.5 or nodule size greater than 2 cm;
- Cannot be completely resected by wedge resection;
- Invasive lung adenocarcinoma or lung malignancy other than lung adenocarcinomadiagnosed cytologically or pathologically;
- Receiving lung cancer surgery before;
- Receiving radiotherapy or chemotherapy.
Study Design
Total Participants: 286
Treatment Group(s): 1
Primary Treatment: Wedge resection
Phase: 3
Study Start date:
November 01, 2023
Estimated Completion Date:
November 30, 2030
Connect with a study center
Fudan University Shanghai Cancer Center
Shanghai,
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.